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METHODS: We retrospectively collected data of sRP for recurrent prostate cancer (PCa) after local non-surgical treatment at 18 tertiary referral centers, from 2000 to 2016. Patient with insufficient follow-up (<6 mo) and/or lacking data on functional outcomes or complications were excluded. The Clavien-Dindo classification was employed to classify complications. Functional outcomes were assessed at baseline (before sRP) and at 6 and/or 12 months follow up.
RESULTS: In total, 395 sRP (n[186 open; n[209 robotic) were included. At baseline, no differences were present apart from follow-up duration (p<0.001), pre-sRP castration resistant PCa proportion (p[0.0055) (higher for open RP) and sRP Gleason (p[0.0159) (higher for robotic sRP). All patients were free from radiological evidence of extranodal metastases. Lower blood loss (p<0.0001) and shorter hospital stay (p<0.0001) were observed for robotic sRP, while no significant differences emerged in major (10.1%,p[0.16) and overall complications (34.9%,p[0.67) . Risk of rectal injuries and fistulas was limited (respectively, 1.58% and 2.02%); anastomotic stricture was more common in open-sRP (16.6% vs 7.7%; p<0.01).
Overall, 57,5% of patients had improved/unchanged continence, whereas 24.6% experienced severe (!3pads/day) incontinence; spontaneous or PDE-5 assisted erections occurred in 8.1% of the cases (15.6% potent before sRP had preserved erectile function compared to pre-sRP). Considering nerve sparing procedures, 3 (11.5%) in 26 men with available results maintained spontaneous or PDE-5 assisted erections. Robotic approach was an independent predictor for continence preservation (OR 0.411, p[0.022) METHODS: We retrospectively reviewed the records of patients treated with radical prostatectomy (RP) from 2010 to 2015 at our institution. Before RP, all patients were confirmed to have prostate cancer based on prostate biopsy. We excluded patients who underwent neoadjuvant therapy. Additionally, we excluded patients who had incomplete mpMRI based on PI-RADS (Prostate Imaging Reporting and Data System). iPCa was defined as having no grade 3 or higher region of interests using a scoring system established by PI-RADS without limitations on interpretation from mpMRI by radiologists. We selected patients with iPCa using this protocol. We analyzed data using univariate and multivariate cox regression analysis, logistic analysis, Kaplan-Meier curves, and receiver operator characteristic curves to predict biochemical recurrence (BCR).
RESULTS: A total of 213 patients with iPCa were selected according to the patient selection protocol. Among them, pathological findings showed that Gleason score (GS) GS6, GS7 and above GS8 were present in 115 cases (54.0%), 78 cases (36.6%), and 20 cases (9.4%), respectively. Further, extracapsular extension (ECE), positive surgical margins (PSM), and lymphovascular invasion (LVI) were present in 28 (13.1%), 18 (8.5%), and 3 cases (1.4%), respectively. Seminal vesicles invasion (SVI) was observed in one case (0.5%). During a median follow-up time of 51 months, BCR was observed 29 cases. Adverse pathology (AP) was defined as above GS8, ECE, SVI and LVI. AP and prostate specific antigen (PSA) were significantly associated with BCR. Moreover, PSA>6.2 ng/ml was suggested as a cut-off value for predicting BCR.
CONCLUSIONS: In our results, cases of iPCa had clinically significant PCa, and AP and poor prognosis were also observed in some. Additionally, we found that PSA is the most clinically reliable predictor of oncologic outcome. We suggest that active treatment and diagnosis should be considered for patients with iPCa with PSA>6.2 ng/ml.
